[The role of immunoglobulin preparations in treatment of allergic diseases].
Intravenous immunoglobulin (IVIG) has been used for many years to treat patients with primary immunodeficiencies. More recently, IVIG has been shown to have antiinflammatory activity when used at substantially higher concentrations. A number of studies have examined the efficacy of IVIG in allergic diseases. For patients with severe refractory asthma, sinusitis, atopic dermatitis, and urticaria, IVIG offers an alternative therapy with relatively few side effects. Although the mechanism by which IVIG may attenuate the allergic response is still undetermined, clinical studies have shown that immunoglobulin therapy can decrease serum IgE levels and increase glucocorticoid binding affinity, while in vitro studies have shown that IVIG can decrease T-cell secretion of TH2 cytokines.
Boznański
Andrzej
A
I Katedra Pediatrii i Klinika Alergologii oraz Kardiologii Dzieciecej Akademii Medycznej we Wrocławiu. aboz@pedalergol.am.wroc.pl
Widerska
Alicja
A
D001249:Asthma / Q000188:drug therapy; D005938:Glucocorticoids / Q000378:metabolism; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy* / Q000378:metabolism; D007073:Immunoglobulin E / Q000097:blood; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000378:metabolism
D005938:Glucocorticoids; D016756:Immunoglobulins, Intravenous; D007073:Immunoglobulin E